Integra LifeSciences Holdings (IART)

Currency in USD
18.23
-0.01(-0.05%)
Real-time Data·
IART is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.7318.45
52 wk Range
8.7020.49
Key Statistics
Prev. Close
18.24
Open
18.1
Day's Range
17.73-18.45
52 wk Range
8.7-20.49
Volume
156.65K
Average Volume (3m)
950.37K
1-Year Change
33.7004%
Book Value / Share
13.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IART Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.56
Upside
+7.27%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

3 Buy
7 Hold
2 Sell
Ratings:
12 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 19.56
(+7.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BMO Capital
Hold18.00-1.26%19.00MaintainJul 30, 2026
Wells Fargo
Hold18.00-1.26%15.00MaintainJul 30, 2026
UBS
Hold19.00+4.22%-New CoverageJul 28, 2026
Truist Securities
Hold19.00+4.22%14.00MaintainJul 16, 2026
BMO Capital
Hold19.00+4.22%-New CoverageJul 09, 2026

Integra LifeSciences Holdings Earnings Call Summary for Q2/2026

  • Integra posted Q2 adjusted EPS of $0.56, beating estimates of $0.48 by 16.7%, driven by operational gains and tariff favorability.
  • Revenue of $418.8M slightly exceeded forecasts but grew only 0.8% reported; full-year guidance unchanged at $1.65B-$1.70B and EPS $2.40-$2.50.
  • Gross margin improved to 61.3% and adjusted EBITDA margin rose to 18.7%, reflecting cost savings and manufacturing efficiencies.
  • Shares fell 6.43% premarket to $18.49 as investors weighed unchanged guidance and concerns over higher H2 interest expense from refinancing.
  • SurgiMend relaunch planned for Q4 2026 with PMA approval expected early 2027; MediHoney and DuraSorb returns targeted for 2027.
Last Updated: 2026-07-29, 09:32 a/m
Read Full Transcript

Earnings

Latest Release
Jul 29, 2026
EPS / Forecast
0.56 / 0.48
Revenue / Forecast
418.8M / 417.62M
EPS Revisions
Last 90 days

IART Income Statement

Compare IART to Peers and Sector

Metrics to compare
IART
Peers
Sector
Relationship
P/E Ratio
−197.0x−22.6x−0.4x
PEG Ratio
−1.99−0.840.00
Price/Book
1.4x3.0x2.6x
Price / LTM Sales
0.9x2.8x3.1x
Upside (Analyst Target)
4.2%28.6%48.4%
Fair Value Upside
Unlock−14.4%6.5%Unlock

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
33.59M43.19%583.80M
Other Institutional Investors
57.76M56.81%1.00B
Public Companies & Retail Investors
0.000.00%0.00
Total
91.35M100.00%1.59B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.13.27%10,319,169179,347
Tru St Partnership LP10.95%8,515,930148,007

People Also Watch

80.74
PARR
-1.70%
330.31
KRYS
+0.60%
65.37
COCO
+0.25%
49.29
ALKS
-0.32%
37.17
OMCL
-1.25%

FAQ

What Is the Integra (IART) Stock Price Today?

The Integra stock price today is 18.23 USD.

What Stock Exchange Does Integra Trade On?

Integra is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Integra?

The stock symbol for Integra is "IART."

What Is the Integra Market Cap?

As of today, Integra market cap is 1.42B USD.

What Is Integra's Earnings Per Share (TTM)?

The Integra EPS (TTM) is -0.10.

When Is the Next Integra Earnings Date?

Integra will release its next earnings report on Nov 04, 2026.

From a Technical Analysis Perspective, Is IART a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Integra Stock Split?

Integra has split 2 times.

How Many Employees Does Integra Have?

Integra has 4427 employees.

What is the current trading status of Integra (IART)?

As of Aug 14, 2026, Integra (IART) is trading at a price of 18.23 USD, with a previous close of 18.24 USD. The stock has fluctuated within a day range of 17.73 USD to 18.45 USD, while its 52-week range spans from 8.70 USD to 20.49 USD.

What Is Integra (IART) Price Target According to Analysts?

The average 12-month price target for Integra is 19.56 USD, with a high estimate of 27 USD and a low estimate of 14 USD. 3 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an +7.27% Upside potential.

What Is the IART Premarket Price?

IART's last pre-market stock price is 18.05 USD. The pre-market share volume is 716.00, and the stock has decreased by -0.19, or -1.04%.

What Is the IART After Hours Price?

IART's last after hours stock price is 18.25 USD, the stock has decreased by 0.01, or 0.05%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.